Oxford, UK – 07 Dec 2023 Download this Press Release as a PDF IngenOx Therapeutics, an Oxford-based biopharmaceutical company, announced that its Chief Medical Officer, Prof. David Kerr had published a review on the use of diagnostic biomarkers to personalise…
Oxford, UK – 6 October 2023 Download this Press Release as a PDF IngenOx Therapeutics, the Oxford-based biopharmaceutical company announced today that it had received separate grants of applications from the Chinese (CNIPA); and European Patent Office for compounds and…
Oxford, UK – 6 July 2023 Download this Press Release as a PDF IngenOx Therapeutics, an Oxford-based clinical-stage biopharma company, has been granted patents for new compounds that inhibit PRMT5. The new patents are for the composition of matter…
Download Press Release as a PDF IngenOx Therapeutics, the Oxford biopharma company announced today that the Hong Kong Drug Office had given approval for a Phase II clinical trial to proceed in treatment-resistant hepatocellular cancer (HCC) patients, combining its drug…
Download Press Release as a PDF IngenOx Therapeutics, the clinical stage Oxford biopharma company announced today the results of collaborative work between the University of Oxford using its zabadinostat drug. In experimental models, zabadinostat was found to potentiate both the…
Celleron Therapeutics and Argonaut Therapeutics have jointly announced today the completion of a merger agreement to form IngenOx Therapeutics. Supported by Oxford Science Enterprises (OSE), the merger of the two University of Oxford spinout companies brings together drug discovery and…
Oxford, UK, 08 Nov 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that Founder and Chief Medical Officer Prof David Kerr CBE had been conferred the “Tianfu Friendship Award” by the Sichuan Provincial…
Oxford, UK, 22 Sep 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that Founder and Chief Medical Officer Prof David Kerr had been made a Fellow of the European Society for Medical Oncology.…
Oxford, UK, 15 August 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announces today that in partnership with the Chinese University of Hong Kong it has successfully received a study grant from the Hong Kong government’s…
Oxford, UK, 29 June 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announced today a 3-year survival rate of 7.3% in late-stage micro-satellite stable colorectal cancer patients in their Phase II clinical trial, following treatment with…